Concord Biotech Limited Cash Flow Quality Index
Concord Biotech Limited cash flow quality index. Concord Biotech Limited (CONCORDBIO) has a Cash Flow Quality Index of 0.67x as of March 2025. Operating cash flow of Rs2.47 Billion is below net income of Rs3.72 Billion, suggesting accrual-heavy earnings not yet converted to cash. See Concord Biotech Limited (CONCORDBIO) flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Concord Biotech Limited (2020–2025)
Cash flow quality index of Concord Biotech Limited from 2020 to 2025. Historical Cash Flow Quality Index for Concord Biotech Limited across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore debt repayment capacity of Concord Biotech Limited to assess how comfortably operating cash covers total debt obligations.
Concord Biotech Limited Cash Flow Quality Index by Year (2020–2025)
Concord Biotech Limited cash flow quality index by year from 2020 to 2025. Year-by-year earnings quality comparison for Concord Biotech Limited. For the full cash flow conversion analysis, see Concord Biotech Limited cash conversion from operations.
| Year | Quality Index | Operating CF (INR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.67x | Rs2.47 Billion | Rs3.72 Billion | ▼ -22.7% |
| 2024 | 0.86x | Rs2.65 Billion | Rs3.08 Billion | ▼ -15.9% |
| 2023 | 1.02x | Rs2.46 Billion | Rs2.40 Billion | ▼ -13.6% |
| 2022 | 1.19x | Rs2.07 Billion | Rs1.75 Billion | ▲ +67.0% |
| 2021 | 0.71x | Rs1.67 Billion | Rs2.35 Billion | ▼ -22.4% |
| 2020 | 0.92x | Rs1.55 Billion | Rs1.69 Billion | — |